Cardiol Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Cardiol Therapeutics Free Cash Flow (FCF) History (CRDL)
Cardiol Therapeutics reported −$23.9M in free cash flow for fiscal 2025, an increase of $1.2M from the previous fiscal year.
View full Cardiol Therapeutics company overviewCardiol Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$23.9M | $1.2M | — | — |
| 2024 | 2024-12-31 | −$25.1M | $162,596 | — | — |
| 2023 | 2023-12-31 | −$25.2M | $2.1M | — | — |
| 2022 | 2022-12-31 | −$27.3M | −$3.7M | — | — |
| 2021 | 2021-12-31 | −$23.6M | −$14.4M | — | −29904.22% |
| 2020 | 2020-12-31 | −$9.2M | — | — | — |
Cardiol Therapeutics quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Cardiol Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$9.2M to −$23.9M, a net decrease of $14.7M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Cardiol Therapeutics filings at SEC.gov ↗